高级搜索

聚类和判别分析法在肺癌六种肿瘤标志物诊断中的应用

冯阳春, 徐怡, 黄艳春

冯阳春, 徐怡, 黄艳春. 聚类和判别分析法在肺癌六种肿瘤标志物诊断中的应用[J]. 肿瘤防治研究, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012
引用本文: 冯阳春, 徐怡, 黄艳春. 聚类和判别分析法在肺癌六种肿瘤标志物诊断中的应用[J]. 肿瘤防治研究, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012
shu
FENG Yangchun, XU Yi, HUANG Yanchun. Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012
Citation: FENG Yangchun, XU Yi, HUANG Yanchun. Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 266-269. DOI: 10.3971/j.issn.1000-8578.2015.03.012
shu

聚类和判别分析法在肺癌六种肿瘤标志物诊断中的应用

  • 830011 乌鲁木齐，新疆医科大学附属肿瘤医院检验科

详细信息
    作者简介:

    冯阳春（1987-），男，硕士，技师，主要从事临床检验诊断学研究

    通讯作者:

    黄艳春，E-mail: huangyanchun0619@sohu.com

  • 中图分类号: R734.2

Application of Cluster Analysis and Discriminant Analysis in Six Kinds of Lung Cancer Tumor Markers

  • Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China

摘要

    摘要
  • 摘要: 目的 探讨聚类和判别分析法在肺癌6种肿瘤标志物诊断中的应用。方法 收集2012年5月至2013年5月新疆医科大学附属肿瘤医院初次入院就诊且最终确诊的肺癌患者342例，在未进行任何治疗前检测其血清中Pro-GRP、CEA、CA125、SCC、CYFRA21-1、NSE的含量。比较六种肿瘤标志物在小细胞肺癌、肺腺癌、肺鳞癌中的差别，应用聚类分析的方法对六个指标进行指标聚类，并对342例样本进行判别分析。结果 NSE和Pro-GRP在小细胞肺癌中的含量明显高于肺鳞癌和肺腺癌；SCC和CYFRA21-1在肺鳞癌中的含量明显高于小细胞肺癌和肺腺癌；CEA和CA125在肺腺癌中的含量明显高于小细胞肺癌和肺鳞癌。聚类分析表明NSE和Pro-GRP是诊断小细胞肺癌的良好指标，而CEA、CA125、SCC、CYFRA21-1却是对诊断非小细胞肺癌具有帮助。利用6种指标建立的判别函数对于小细胞肺癌的诊断符合率为93.3%；对于非小细胞肺癌的诊断符合率为83.0%。结论 利用聚类分析和判别分析的统计方法可以证明NSE、Pro-GRP、CEA、CA125、SCC、CYFRA21-1对肺癌不同病理分型诊断具有不同的应用价值。

     

    Abstract: Objective To investigate the application of cluster analysis and discriminant analysis in diagnosing different pathological types of lung cancer by six kinds of tumor markers. Methods We collected 342 patients who received the first hospitalization and were finally diagnosed as lung cancer in Tumor Hospital Affiliated to Xinjiang Medical University from May 2012 to May 2013. Serum concentrations of SCC, CYFRA 21-1, CEA, CA125, Pro-GRP and NSE were assayed for every patient before any treatment. We compared the differences of the six tumor markers among SCLC, lung adenocarcinoma and lung squamous carcinoma. We clustered the six tumor marker indexes by cluster analysis, and samples of 342 cases of samples were analyzed by discriminant analysis. Results NSE and Pro-GRP levels were significantly higher in SCLC tissues than those in squamous carcinoma and lung adenocarcinoma tissues. SCC and CYFRA21-1 were obviously higher in lung squamous carcinoma tissues than those in SCLC and lung adenocarcinoma tissues; CEA and CA125 levels were significantly higher in lung adenocarcinoma tissues than those in SCLC and lung squamous carcinoma tissues. Cluster analysis showed that NSE and Pro-GRP was helpful for diagnosing SCLC, and CEA, CA125, SCC, CYFRA21-1 were beneficial in the diagnosis of NSCLC. The diagnosis coincidence rate for SCLC was 93.3% and for NSCLC was 83.0% by the discrimination function established on six tumor markers. Conclusion Cluster analysis and discriminant analysis indicate that NSE, Pro-GRP, CEA, CA125, SCC and CYFRA21-1 have certain diagnostic value in diagnosing the different pathological types of lung cancer.

     

    • HTML全文
    • 参考文献(18)
  • [1] Mao YS, Gao YN, He J, et al. Association of molecular biology of lung cancers and their metastasis and prognosis[J]. Zhonghua Zhong Liu Za Zhi, 2006, 28(8): 632-4.[毛友生, 高燕宁, 赫捷, 等. 肺癌分子生物学特性与转移和预后的关系[J]. 中华肿瘤杂志, 20 06, 8(8): 632-4.]
    [2] Yang HJ, Gu Y, Chen C, et al. Diagnostic value of pro-gastrinreleasing peptide for small cell lung cancer: a meta-analysis[J]. Clin Chem Lab Med, 2011, 49(6): 1039-46.
    [3] Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making[J]. Biomark Med, 20 08, 2(6): 577-86.
    [4] Gao YC, Wang MQ, Lu Y, et al. The value of serum tumor markers in the diagnosis of lung cancer patients[J]. Zhonghua Jie He He Hu Xi Za Zhi, 2005, 28(4): 268-9.[高云朝, 王美琴, 陆云, 等. 血 清肿瘤标志物的检测对肺癌患者的诊断价值[J]. 中华结核和呼 吸杂志, 2005, 28(4): 268-9.]
    [5] Plebani M, Basso D, Navaglia F, et al. Clinical evaluation of seven tumor market in lung cancer diagnosis: can any combination improve the results[J]. Br J Cancer, 1995, 72(1): 170-3.
    [6] Sun J, Liu J, Yang BJ. The clinical value of serum pro-gastrinreleasing peptide and neuron-specific enolase for small-cell lung cancer[J]. Xian Dai Jian Yan Yi Xue Za Zhi, 2005, 20(4): 11-3.[孙 静, 刘静, 杨炳军. 胃泌素释放肽前体和神经元特异性烯醇化 酶对小细胞肺癌的临床应用价值[J]. 现代检验医学杂志, 2005, 20 (4): 11-3.]
    [7] Jin X, Chen JK, Tong YL, et al. Clinical significance of Pro-GRP in diagnosis of SCLC[J].Jun Shi Yi Xue Ke Xue Yuan Yuan Kan, 20 06, 30(4): 354-6.[金欣, 陈建魁, 佟雅丽, 等. 血清ProGRP对 小细胞肺癌的诊断和疗效判断价值[J]. 军事医学科学院院刊, 20 06, 30(4): 354-6.]
    [8] Duffy MJ, O’Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients[J]. Cancer Treat Rev, 2011, 37(2): 151-9.
    [9] Sturgeon CM, Hoffman BR, Chan DW, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in clinical practice: quality requirements[J]. Clin Chem, 2008, 54(8): e1-10.
    [10] Wang Y, Huang LS, Huang WC. Clinical value of three kinds of serum tumor markers in the diagnosis of lung cancer[J]. Yi Xue Lin Chuang Yan Jiu, 2006, 23(5): 661-2, 665.[王英, 黄玲莎, 黄 文成. 三种血清肿瘤标志物在肺癌诊断中的临床价值[J]. 医学 临床研究, 2006, 23(5): 661-2, 665.]
    [11] Ma J, Zhao J, Jiang HJ. The application of pleural effusions tumor markers combined detection for lung cancer pathology classification and clinical staging[J]. Lin Chuang Yi Xue, 2008, 28 (7): 51-3.[马静, 赵俊, 蒋会娟．胸腔积液肿瘤标志物联合检 测在肺癌病理分型及临床分期中的应用[J]. 临床医学, 2008, 28 (7): 51-3.]
    [12] Deng X, Xiu X, Tan AG. Prognostic significance of CYFRA21-1 and CEA in stage Ⅲ non-small cell lung cancer[J]. Zhongguo Shi Yan Zhen Duan Xue, 2007, 11(6): 779-81.[邓湘, 修霞, 谭爱国. CYFRA21-1和CEA对Ⅲ期非小细胞肺癌患者的临床预后意义 [J] 中国实验诊断学, 2007, 11(6): 779-81.]
    [13] Merle P, Janicot H, Filaire M, et al. Early CYFRA21-1 variation predicts tool response to chemotherapy and survival in locally advanced non-small cell cancer patients[J]. Int J Biol Markers, 20 04, 19(4): 310-5.
    [14] Yang L, Tan LX, Jia ZC, et al. Lung cancers 69 cases sufferer,s serum tumor marker measurement analysis[J].Zhongguo Xian Dai Yi Xue Za Zhi, 2006, 8(2): 20-2.[杨玲, 谭立欣, 贾支朝, 等. 肺 癌患者69例血清肿瘤标志物测定分析[J]. 中国现代医学杂志, 20 06, 8(2): 20-2.]
    [15] Guo DW, Meng DY, Ding XN, et al. Serum CEA, CA125 levels analysis and its clinical significance for lung cancer patients[J]. Zhong Liu Fang Zhi Yan Jiu, 2002, 29(4): 275.[郭大文, 孟冬娅, 丁笑难, 等. 肺癌患者血清CEA、CA125水平分析及其临床意 义[J] 肿瘤防治研究, 2002, 29(4): 275.]
    [16] Molina R, Augé JM, Bosch X, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology[J]. Tumour Biol, 2009, 30 (3): 121-9.
    [17] Li MX, Wang D, Li ZP, et al. Establishment of diagnostic equation within serum multiple tumor markers and its significance in diagnosis and classify of lung cancer[J].Chongqing Yi Xue, 2007, 36 (19): 1926-8, 1972.[李梦侠, 王东, 李增鹏, 等. 血清多肿瘤标 志物判别方程建立及其对肺癌诊断及分类的意义[J]. 重庆医 学, 2007, 36(19): 1926-8, 1972.]
    [18] Nan YD, Tian YX, Yang SY, et al. Fisher discriminated analysis of Serum tumor markers on SCLC and NSCLC[J]. Xian Dai Zhong Liu Yi Xue, 2008, 16(3): 365-7.[南岩东, 田应选, 杨拴盈, 等. 血清肿瘤标志物对SCLC和NSCLC的Fisher判别分析[J]. 现 代肿瘤医学, 2008, 16(3): 365-7.]
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1155
  • HTML全文浏览量:  419
  • PDF下载量:  751
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-04-04
  • 修回日期:  2014-09-10
  • 刊出日期:  2015-03-24

目录

摘要
HTML全文
    参考文献(18)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11627569 今日访问：35329

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭